# Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy

> **NCT02495181** · PHASE4 · COMPLETED · sponsor: **Association for Innovation and Biomedical Research on Light and Image** · enrollment: 50 (actual)

## Conditions studied

- Polypoidal Choroidal Vasculopathy

## Interventions

- **DRUG:** Intravitreal Aflibercept

## Key facts

- **NCT ID:** NCT02495181
- **Lead sponsor:** Association for Innovation and Biomedical Research on Light and Image
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-23
- **Primary completion:** 2017-08-22
- **Final completion:** 2019-12-17
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02495181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02495181, "Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02495181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*